<DOC>
	<DOCNO>NCT00768079</DOCNO>
	<brief_summary>The study evaluate effect two IV dose regimen MEDI-563 proportion adult subject asthma exacerbation require urgent healthcare visit treatment acute asthma exacerbation .</brief_summary>
	<brief_title>A Phase 2 Study Evaluate Safety Efficacy Intravenously Administered MEDI-563</brief_title>
	<detailed_description>The study evaluate effect two IV dose regimen MEDI-563 ( 0.3 1.0 mg/kg ) proportion adult subject asthma exacerbation ( relapse de novo ) require urgent healthcare visit treatment acute asthma exacerbation .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<criteria>Male female subject age 18 60 year time administration investigational product . Written inform consent HIPAA authorization ( applies cover entity US ) obtain subject/legal representative prior performing protocolrelated procedure , include screen evaluation . Physiciandiagnosed asthma duration great equal 2 year medical chart subject report . Had asthma exacerbation require urgent care year prior screen . Meets NHLBI persistent asthma 3 month prior current urgent healthcare visit . Current asthma exacerbation must last great equal 2 hour prior arrival urgent healthcare set . Requires least 2 treatment inhaled bronchodilator current asthma exacerbation urgent healthcare set within emergency medical system ( EMS ) great equal 1 hour . Shows FEV1 PEF 70 % predict 1 hour treatment current asthma exacerbation . Women childbearing potential , unless surgically sterile ( include tubal ligation ) and/or least 2 year postmenopausal , must use 2 effective method avoid pregnancy ( include oral , transdermal , implanted contraceptive , intrauterine device , female condom spermicide , diaphragm spermicide , cervical cap , abstinence , use condom spermicide sexual partner , sterile sexual partner ) screen end study ( Study Day 84 ; Cessation birth control point discuss responsible physician ) . Men , unless surgically sterile , must likewise practice 2 effective method birth control ( condom spermicide abstinence ) must use precaution Study Day 0 Study Day 84 . Otherwise healthy medical history physical examination . A chest xray normal asthmatic population excludes alternative diagnosis per investigation . Ability complete followup period Study Day 168 require protocol . The investigator determine subject clinically stable FEV1 , great equal 30 % predict prior receive investigational product Study Day 0 . Known history allergy reaction component investigational product formulation . Acute illness asthma start study . Fever &gt; 38.6°C ( &gt; 101.5°F ) . Current acute asthma attack due aspirininduced asthma . Current asthma episode anaphylactoid/anaphylactic reaction present acute bronchospasm . Evidence clinically significant nonrespiratory active infection , include ongoing chronic infection . History current prolong diarrhea , abdominal pain , and/or blood mucus stool minor symptom AND exposure stream lake water , expose someone parasitic infection ( like family member ) , study subject travel outside US and/or Canada within last year . Use immunosuppressive medication ( except oral prednisone inhale topical corticosteroid ) within 30 day randomization study . Have receive Xolair ( TM ) within 6 month randomization study . Receipt immunoglobulin blood product within 30 day randomization study . Receipt investigational drug therapy within 6 month first dose investigational product study Study Day 168 . History primary immunodeficiency . Previous medical history , evidence , intercurrent illness may compromise safety subject study . History clinically significant abnormality ECG opinion investigator . Pregnancy ( must negative serum pregnancy test prior first dose investigational product ) . Breastfeeding lactate woman . History treatment alcohol drug abuse within past year . Diagnosis COPD healthcare professional . Evidence clinically significant systemic disease physical examination . History cancer except basal cell carcinoma situ carcinoma cervix treat apparent success curative therapy &gt; 1 year prior entry malignancy treat apparent success curative therapy &gt; 5 year prior entry . Known exposure inhale occupational agent fumes establish diagnosis occupational asthma . Any condition ( ie , impend ventilatory failure hemodynamic compromise ) , opinion investigator , would interfere evaluation investigational product interpretation study result . Any employee clinical study site involve conduct study . History cigarette smoking &gt; 20 pack year . Previously receive MEDI563 . Asthma exacerbation due acute inhalational exposure .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Benralizumab</keyword>
	<keyword>MEDI-563</keyword>
	<keyword>Asthma</keyword>
</DOC>